atai Life Sciences Announces Pricing of Upsized Initial Public Offering
June 17 2021 - 11:21PM
atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, today announced the pricing of its upsized
initial public offering in the United States of 15,000,000 common
shares at a price to the public of $15.00 per share. All common
shares are being offered by atai. The gross proceeds of the
offering, before deducting underwriting discounts and commissions
and other offering expenses payable by atai, are expected to be
$225.0 million. In addition, atai has granted the underwriters a
30-day option to purchase up to an additional 2,250,000 common
shares at the initial public offering price, less underwriting
discounts and commissions. The offering is expected to close on
June 22, 2021, subject to customary closing conditions.
atai’s common shares are expected to begin trading on the Nasdaq
Global Market on June 18, 2021 under the ticker symbol
“ATAI.”
Credit Suisse, Citigroup, Cowen, and Berenberg are acting as
book-running managers for the proposed offering. Cantor, RBC
Capital Markets and Canaccord Genuity are also acting as
book-running managers for the proposed offering.
This offering is being made only by means of a prospectus.
Copies of the final prospectus relating to this offering may be
obtained, when available, by contacting: Credit Suisse Securities
(USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens
Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or
by email at usa.prospectus@credit-suisse.com; Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146 or by
email at prospectus@citi.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, Attention: Prospectus Department, or by telephone
at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com; or, Berenberg Capital
Markets LLC, Attention: Investment Banking, 1251 Avenue of the
Americas, 53rd Floor, New York, New York 10020, or by telephone at
+1 (646) 949-9000, or by e-mail at
prospectusrequests@berenberg-us.com.
A registration statement relating to the securities being sold
in the offering has been declared effective by the U.S. Securities
and Exchange Commission (the “SEC”) on June 17, 2021. This
press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or
jurisdiction.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape, as well as the emergence of
therapies that previously may have been overlooked or underused,
including psychedelic compounds and digital therapeutics. atai is
headquartered in Berlin, with offices in New York and London.
Investor Contact:Greg Weaveratai – Chief
Financial OfficerEmail: greg.weaver@atai.life
Media Contact:Anne DonohoeKCSA Strategic
CommunicationsPhone: +1 (212) 896-1265Email: atai@KCSA.com
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jun 2024 to Jul 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Jul 2023 to Jul 2024